COVID-19
Mirxes offers complete
COVID-19 testing solutions
Starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests and mutation panels for quick identification of key variants.
Swab Collection System
Collect, handle, and store nasal and throat swab samples safely and stably
(up to two weeks at room temperature).
Saliva Collection Kit
Easy and convenient collection of saliva samples which can be transported
and stored stably up to 15 days at room temperature.
RNA Extraction Kits
MAGec RNA Extraction Kits for easy and reliable RNA extraction using
guanidine-based lysis and magnetic bead-based isolation.
RNA Extraction Instruments
MAGec RNA Extraction Kits for easy and reliable RNA extraction using
guanidine-based lysis and magnetic bead-based isolation.
Fortitude 2.1 Test Kit
Tested and proven RT-PCR test detecting 2 SARS-CoV-2 ORF regions. More than 7 million tests deployed in over 45 countries.
Fortitude Syndromic Panel
Fortitude SARS-CoV-2 & Flu A/B test kit. Detects 2 SARS-CoV-2 genes (ORF and N).
CoVClear Mutation Panel
RUO test to detect key SARS-CoV-2 mutations for early identification of COVID-19 positive patients infected by variants of concern.
The World Health Organization (WHO) has defined a SARS-CoV-2 isolate as a
variant of interest (VOI) if it is phenotypically changed compared to a reference
isolate of has a genome with mutations that lead to amino acid changes associated
with established or suspected phenotypic implications; AND has been identified
to cause community transmission/multiple COVID-19 cases/clusters, or has been
detected in multiple countries.
A VOI is further classified as a variant of concern (VOC) if, through a comparative
assessment, it has been demonstrated to be associated with:
- Increase in transmissibility of detrimental change in COVID-19 epidemiology;
- Increase in virulence or change in clinical disease presentation; or
- Decrease in effectiveness of public health and social measures or available
diagnostics, vaccines, therapeutics.
WHO-designated SARS-CoV-2 variants of concern (VOCs)
As of 29 November 2021
| WHO Label | Pango Lineage | First Identified | Spike Protein Substitutions |
|---|---|---|---|
| Alpha | B.1.1.7 | United Kingdom | N501Y, 69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*) |
| Beta | B.1.351 | South Africa | D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V |
| Gamma | P.1 | Brazil | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I |
| Delta | B.1.617.2 | India | T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R, D950N |
| Omicron | B.1.1.529 | South Africa | – |
WHO-designated SARS-CoV-2 variants of interest (VOIs)
As of 29 November 2021
| WHO Label | Pango Lineage | First Identified | Spike Protein Substitutions |
|---|---|---|---|
| Epsilon | B.1.427 | US (California) | L452R, D614G |
| Epsilon | B.1.429 | US (California) | S13I, W152C, L452R, D614G |
| Eta | B.1.525 | UK/Nigeria | A67V, 69del, 70del, 144del, E484K, D614G, Q677H, F888L |
| Iota | B.1.526 | US (New York) | L5F, (D80G*), T95I, (Y144-*), (F157S*), D253G, (L452R*), (S477N*), E484K, D614G, A701V, (T859N*), (D950H*), (Q957R*) |
| Kappa | B.1.617.1 | India | (T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H |
| None | B.1.617.3 | India | T19R, G142D, L452R, E484Q, D614G, P681R, D950N |
| Lambda | C.37 | Peru | G75V, T76I, 246-252del, L452Q, F490S, D614G, T859N |
| Mu | B.1.621 | Colombia | E484K, N501Y, P681H |
Detection of key SARS-CoV-2 variants by MiRXES RT-PCR test kits
| Sequence Homology with | Fortitude 2.1 | Fortitude Syndromic Panel |
|---|---|---|
| All SARS-CoV-2 ORF target sequences | 99.4 | 97.6 |
| All SARS-CoV-2 N gene target sequences | – | 98.1 |
| Delta (B.1.617.2) | 100.00 | 99.90 |
| Alpha (B.1.1.7) | 99.79 | 99.99 |
| Beta (B.1.351) | 100.00 | 99.96 |
| Gamma (P.1) | 99.98 | 99.98 |
| Omicron (B.1.1.529) | 100.00 | 100.00 |
| Lambda (C.37) | 100.00 | 99.66 |
| Mu (B.1.621) | 100.00 | 100.00 |